New York, NY / Washington, D.C. – The following is the response of Jeff Stier, director of the National Center’s Risk Analysis Division, to the decision of the drug company Chimerix to make an experimental drug, Brincidofovir, available to an ailing seven-year-old boy: I’m happy … Continue reading Statement of Risk Analysis Division Director Jeff Stier in Response to Chimerix Decision to Make Experimental Drug Brincidofovir Available to Seven-Year-Old Boy